Acute kidney injury in statin initiators by Layton, J. Bradley et al.
Acute kidney injury in statin initiators
J. Bradley Layton, PhD1,2, M. Alan Brookhart, PhD1, Michele Jonsson Funk, PhD1, Ross J.
Simpson Jr., MD, PhD3, Virginia Pate, MS1, Til Stürmer, MD, PhD1, and Abhijit V.
Kshirsagar, MD, MPH2
1Department of Epidemiology, University of North Carolina at Chapel Hill
2Division of Nephrology, University of North Carolina at Chapel Hill
3Division of Cardiology, Department of Medicine, University of North Carolina at Chapel Hill
Abstract
Purpose—Statins are widely used for preventing cardiovascular disease, yet recent reports
suggest an increased risk of acute kidney injury (AKI). We estimated the one-year risk of AKI
associated with statin initiation and determined the comparative safety of individual statin
formulations.
Methods—We performed a cohort study in insurance billing data from commercial and
Medicare insurance plans in the United States for the years 2000—2010. We identified statin
initiators and non-users with histories of medication use and healthcare utilization. AKI diagnosis
codes were identified in the one year following the index date. We estimated hazard ratios (HR)
and 95% confidence intervals (CI) with adjusted and propensity score (PS)-matched Cox-
proportional hazards models. Models were run separately in insurance groups and adjusted for
cardiovascular and renal risk factors, markers of healthcare utilization, and other medication use.
Results—We identified 3,905,155 statin initiators and 2,817,621 eligible non-users. The adjusted
HR of AKI in statin initiators compared to non-users was: commercial, HR=1.04 (95% CI: 0.99,
1.09); Medicare, HR=0.72 (95% CI: 0.70, 0.75). PS-matching yielded: commercial, HR=0.82
(95% CI: 0.78, 0.87); Medicare HR=0.66 (95% CI: 0.63, 0.69). As individual formulations,
higher-potency simvastatin was associated with an increased risk of AKI over lower-potency
simvastatin in adjusted models: commercial, HR=1.42 (95% CI: 1.28, 1.58Medicare, HR=1.24
(95% CI: 1.15, 1.35).
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Conclusions—As a class, statin initiation was not associated with an increase in AKI. However,
higher-potency simvastatin did exhibit an increased AKI risk.
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Introduction
Statin use has become widespread in the United States (US) over the past decade.1 Statins
are a mainstay of lipid management and an integral part of both primary and secondary
cardiovascular disease (CVD) prevention.1–3 It has been suggested that statins have anti-
inflammatory4 and other pleiotropic effects5–7 beyond their lipid-lowering function.
Consequently, their use has been advocated in populations previously considered at low risk
for CVD,8–10 raising new concerns about their renal safety profile. Previous data suggests
that they are generally well-tolerated by the kidneys with two notable exceptions: myopathy-
induced acute kidney injury (AKI) mediated by rhabdomyolysis;11,12 and proteinuria in
rosuvastatin users.13 Expert panels have concluded that statins do not lead to AKI or tubular
injury in the absence of myopathy, 14,15 however the primary data source for these
recommendations were intervention studies designed to detect beneficial effects which may
be too small to detect rare adverse events. In contrast, reports from the Food and Drug
Administration reporting system16 suggest that statins may be associated with increased
AKI risk, and, a study of over 2 million individuals from the United Kingdom demonstrated
a nearly two-fold increased risk of AKI with statin use, with a dose response effect, but no
apparent differences by potency.17 Other recent reports suggest increased AKI in higher-
versus lower-potency statins.18,19 Non-randomized studies of statins are complicated by the
lack of an exchangeable comparator drug or an easily identifiable comparable non-user
group; treatment effect estimates can vary widely depending on the referent used. Clinical
trials or well-designed observational studies would employ a comparison group of non-users
or other medication users with a similar risk of the outcome. However, it is difficult to
identify an exchangeable comparison group in non-randomized settings,20 particularly using
administrative claims where difficult-to-measure behavioral and lifestyle factors, access to
and utilization of healthcare, and non-billable clinical factors (obesity, smoking, family
history, etc.) can all contribute to both the risk of AKI and statin initiation. Prior studies17
note large differences in patient health status between statin users and non-users, potentially
introducing confounding by indication.
We conducted a study of the renal safety of statins in a large population-based cohort in the
US. We examined the one-year risk of AKI among statin initiators versus non-users.
Furthermore, we studied the comparative renal safety of individual statin formulations, and
of higher-potency versus lower-potency statins.
Methods
Study population
We employed two large employer-based insurance claims databases: the Truven Health
Analytics MarketScan® Commercial Claims and Encounters and Medicare Supplemental
and Coordination of Benefits databases. These are compilations of insurance billing data
from large, employer-based insurance plans from across the US. Adjudicated, paid inpatient,
outpatient and pharmacy claims, and plan enrollment information are available in the
databases for employees, dependents and retirees. All analyses were performed separately in
the two databases: commercial, employer-based insurance (ages 40 – 64); and Medicare
supplementary insurance (ages 65+).
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This analysis using deidentified billing claims was ruled exempt from further review by the
Institutional Review Board of the University of North Carolina at Chapel Hill (UNC).
Treatment ascertainment
We implemented a new user design21 where statin initiators were identified from pharmacy
dispensing claims following 180 days without a statin prescription (see Figure 1). We
required at least one, non-statin medication claim during the 180-day baseline period to
ensure pharmacy benefit utilization. The formulation of the index statin prescription was
labeled as either higher-potency or lower-potency based on formulation and dosage (see
Table 1). Initiators of cerivastatin sodium were excluded due to its documented risk of
myopathy and rhabdomyolysis and subsequent removal from the market.22,23
A cohort of healthcare-seeking non-users was obtained by identifying individuals with an
outpatient physician’s visit with a procedure code for an office visit or consultation (Current
Procedural Terminology codes 99201–99205, 99211–99215, 99241–99245, 99271–99275)
following 180 statin-free days. Similarly to the statin initiators, non-users were required to
have at least one other medication dispensing during baseline. If a patient had eligible
periods of non-use and initiation, only the first statin-initiation period was considered.
The date of the initial statin prescription (for initiators) or physician’s visit (for non-users)
was considered the index date. The patient entered the cohort on the following day and was
considered a statin initiator or non-user in a first exposure carried forward analysis to avoid
potential bias by informative censoring due to discontinuation because of early muscle or
renal symptoms.
Outcome Ascertainment
Inpatient and outpatient claims were searched for International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes for acute renal failure
(ARF) (ICD-9-CM 584.5 – 584.9) for up to one year following the index date or until
censoring due to end of study or plan disenrollment. The validity of these codes has been
investigated24,25; the positive predictive value varied widely across populations and
reference standards (median, 67%; range. 15%–96%). The sensitivity has been shown to be
quite low depending on the reference standard (26.2% – 47.6%), but the specificity is
consistently very high (97.7% – 99.2%). Both statin initiators and non-users have histories
of medication use and physician observation, so it seems unlikely that differential
misclassification of AKI status would occur between treatment groups. Valid relative effect
measures can still be estimated in situations with very high specificity under the assumption
of nondifferential misclassification across treatment groups.26,27 We considered an
expanded renal failure definition as a sensitivity analysis which included ARF, end-stage
renal disease (ICD-9-CM 585.6), unspecified renal failure (ICD-9-CD 586), or a dialysis
procedure code.
Covariate information
Inpatient and outpatient claims during the baseline period, including the index date, were
investigated for diagnosis and procedure codes for cardiovascular and renal risk factors,
recent acute events, healthcare utilization, and CVD management. For a complete list of
considered covariates, see Table 2.
Pharmacy dispensing claims during the baseline window were searched for prevalent use of
additional medications. Medications that were not used during the baseline window but were
newly-initiated within one day of the index date (day −1, 0, or 1)were considered as
concurrently initiated medications and were included as separate variables in the analysis.
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To restrict to those without a history of renal failure, we excluded individuals with baseline
diagnoses of ARF, ESRD, unspecified renal failure, or a procedure code for dialysis.
Statistical analyses
We estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) with
multivariable Cox proportional hazards models. Follow-up began the day after the index
date and continued until censoring at the first occurrence of: the event of interest; plan
disenrollment; one year after the index date; or end of the study period (December 31,
2010). We repeated the analyses stratified by sex, and within clinically-relevant subgroups
at higher-risk for AKI—those with diabetes, hypertension or chronic kidney disease (CKD)
—or those with acute coronary syndrome (ACS) occurring within the 20 days prior to the
index date. We also estimated the comparative safety of higher-potency versus lower-
potency statins and of individual statin formulations versus lower-potency simvastatin, as
lower-potency simvastatin was the most broadly-used formulation in our sample.
All analyses were performed using SAS 9.2 (SAS Institute, Inc., Cary, NC).
Propensity score methods
We estimated the predicted probability, or propensity score (PS) of statin initiation for each
comparison using the measured covariates in logistic regression models. The distribution of
the PS by treatment group was plotted to assess the extent to which the treatment groups
appeared exchangeable with respect to the measured confounders. To assess treatment effect
heterogeneity, we created 50 equal strata along the PS distribution and plotted the estimated
the HRs within each strata.
We 1:1 matched non-users to initiators, matching to the fifth decimal place if possible using
a greedy matching algorithm.28 Non-matching individuals were excluded from the analysis,
and the HR was estimated within the matched cohort. This method estimates the effect of
the treatment in those who received treatment and were successfully matched to non-users,
rather than in the entire population29.
For the comparative formulation safety analysis, each formulation was weighted to the PS
distribution of the low-potency simvastatin referent with a weight of: (1−PS)/PS. This
created comparisons of each formulation with the same referent, creating directly
comparable effect estimates.
Results
Statin initiators vs. non-users
The distribution of covariates between the treatment groups by insurance is shown in Table
2.
Ages 40 – 64: Commercial insurance—We identified 2,731,839 statin initiators and
2,461,591 eligible non-users. Statin initiators filled an average of 4.7 (SD 3.4) prescriptions
during the year follow-up period for a mean of 207 (SD 106) days of prescription coverage.
31% of the initiators had continuous statin coverage throughout the entire year. Among the
non-users, 0.5% initiated a statin during follow-up.
Statin initiators were older, had more CVD, more healthcare interactions, more comorbidity,
and had more medication use than non-users. PS non-overlap between the treatment groups
was pronounced (see Figure 2).
Layton et al. Page 4













AKI was observed during one-year follow-up in 0.5% of the statin initiators and in 0.2% of
the non-users. Crude Cox-proportional hazards models in the unmatched cohort revealed
HR=2.81 (95% CI: 2.71, 2.91). The effect estimate was attenuated by multivariable
adjustment to HR=1.04 (95% CI: 0.99, 1.09) (see Table 3). Upon propensity score matching
of the statin initiators to non-users, 30.9% of the total sample successfully matched,
resulting in HR=0.82 (95% CI: 0.78, 0.87). Treatment effect heterogeneity was observed
along the distribution of the PS (see Figure 3), with substantially increased HRs in the lower
extreme. The portions of the PS distribution with greatest overlap between treatment groups
(approximately PS 0.3–0.7) which were retained in the PS-matched analysis (Figure 2)
corresponded with the areas with lowest HR estimates (Figure 3).
Ages 65+: Medicare—Statin use was much more common among the Medicare
population; we identified 1,173,316 eligible statin initiators and 356,030 eligible non-users.
Statin initiators filled a mean of 4.6 (SD 3.2) prescriptions during the follow-up year for a
mean of 217 (SD 98) days covered. 22.5% of the initiators maintained active statin
prescriptions for the full year. Of the non-users, 0.8% initiated a statin during follow-up
The treatment groups were comparable in age, yet the statin initiators had more CVD,
comorbidities, acute events, healthcare interactions, and medication use and co-initiation
than non-users. PS overlap was greater in the Medicare group than the commercially
insured, but there were still areas of considerable non-exchangeability, particularly above PS
0.8 (see Figure 2).
AKI was observed in 2.0% of the initiators and 1.5% of the non-users during follow-up. The
crude HR was 1.32 (95% CI: 1.28, 1.35), and after adjustment, it changed to HR=0.72 (95%
CI: 0.70, 0.75). Upon propensity score matching, 35.7% of the total sample successfully
matched, resulting in HR= 0.66 (95% CI: 0.63, 0.69). When stratified by the PS distribution,
the HR estimates were much more homogeneous (see Figure 3).
Sensitivity Analysis—In both age groups, when the expanded kidney failure outcome
definition was considered, the effect measure estimates remained almost identical.
Subgroup Analyses—The rates of AKI were highest in those with CKD in both age
groups. AKI occurrence was higher in all subgroups among the older Medicare groups than
in the younger commercially insured. However, the effect of statin initiation appeared
relatively constant over all subgroups within each estimation technique, with effect measure
estimates tending to be lower among the Medicare group (see Table 4). Statin use was not
associated with an increased risk of AKI in any subgroup.
Higher-potency vs. lower-potency initiators
In the commercially insured statin initiators, 27.0% initiated a higher-potency statin. Among
the Medicare initiators, 24.4% first used a higher-potency statin. In both groups, all effect
measure estimation techniques yielded similar, minimally elevated risk estimated of higher-
potency statin initiation versus lower-potency statins on AKI (see Table 3). PS distribution
overlap was very good in these comparisons (see Web Appendix 1).
Comparative safety of statin formulations
The risk of AKI in individual statin formulations was compared to lower-potency
simvastatin within insurance groups. See Web Appendix 2 for PS distribution plots, which
demonstrate very good overlap for each comparison. Lower-potency simvastatin-
standardized models revealed generally similar hazards of AKI among the various
formulations. Most formulations showed a comparable risk to that in lower-potency
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simvastatin (see Figure 4). In both age groups, adjusted models for higher-potency
simvastatin demonstrated an increased one-year AKI risk: commercial, HR = 1.42 (95% CI:
1.28, 1.58); Medicare, HR = 1.24 (95% CI: 1.15, 1.35). Additionally, lower-potency
atorvastatin and fluvastatin tended to carry the least AKI risk.
Discussion
In this relatively low-risk cohort of over 6.5 million individuals, we found that the
cumulative risk for AKI in statin initiators was about 0.5% in commercially-insured users
and 2.0% in Medicare initiators. As a class, statin initiation was not associated with AKI
after adjustment for known confounding variables; these findings remained constant with PS
matching. However, we did find that higher-potency simvastatin was associated with an
increased risk of AKI compared to lower-potency simvastatin among both commercially and
Medicare insured adults. The increased risk of AKI associated with higher-potency
simvastatin adds another potential safety concern to the documented risk of mylagias30 that
has already prompted a safety warning from the Food and Drug Administration31. The
greatly increased crude hazard ratios (commercially insured: HR=2.93, 95% CI: 2.61, 3.28;
Medicare: HR=1.52, 95%CI: 1.41, 1.65) suggest that higher-potency simvastatin is used in
higher risk patient populations than other statins, and the potential for residual confounding
remains.
Consistent with some prior studies23,32, we did not observe a class effect of statins on renal
safety. This analysis, with a sample size of over 6 million individuals, is arguably better
powered to detect potential harms than previous analyses.
However, the findings of the study contrast markedly with results from a population-based
investigation from the United Kingdom17 which demonstrated an increased risk of AKI
associated with statin use (54% increase for women and 67% men) compared to non-use,
and a greater risk of AKI with increasing dose of agent. A potential explanation for the
difference is the composition of the non-user comparison group. The choice of comparison
groups for studies of drug effects can have substantial influence on effect estimates20. Using
a general sample of non-users may introduce younger, healthier individuals without the
indication for treatment resulting in residual confounding by indication, as statin users are
more likely to have high cholesterol levels, be treated for CVD, have acute CVD events, and
have more comorbidities than younger, healthier controls who are not being treated or
evaluated by physicians. To avoid this bias, we restricted our non-user group to individuals
with a history of medication use and outpatient physician visits, creating a comparison group
with similar healthcare utilization. Additionally, we performed comparisons between
different statin-initiating groups (higher- versus lower-potency statins, individual
formulations).
When compared with non-users, statin initiators tended to be have more risk factors, more
healthcare utilization, and use more medications than non-users. However, PS methods
allowed us to describe the exchangeability of treatment groups relative to measured
confounders, identify areas of equipoise even in the presence of substantial non-overlap, and
describe treatment effect heterogeneity over the propensity score distribution. This was
evident particularly in the younger, commercially-insured population: at the lower
propensity scores (less than 0.2), there were marked increased HR in the statin users at low
PS. Both the initiators and non-users in this PS appear to have very few indications for statin
treatment and few renal risk factors, yet the statin users experience more much more AKI.
This could largely be attributed to confounding by unmeasured factors, including rare
genetic disorders, extreme family histories, etc. which would lead to AKI and statin
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treatment in those without coded traditional risk factors. Characteristics were much better
balanced within potency and formulation treatment groups.
Surprisingly, the results of the PS analyses suggest a modest protective effect of statin use
against one-year risk of AKI. While these findings were robust across renal failure
definitions, they should be interpreted conservatively. The a priori intent of the analysis was
to examine potential renal injury associated with statin initiation, rather than benefit.
Furthermore, given the low occurrence of AKI in this relatively low-risk population, the
estimated absolute reduction of AKI in statin initiators may not be clinically meaningful. A
large proportion of the sample failed to match, reducing the generalizability of the PS-
matched estimates. However, the non-matching were those without equipoise between statin
treatment and non-treatment—either highly likely or very unlikely to have received statin
treatment. Therefore, the resulting matched population represents those patients of greatest
interest in this study of a potentially rare adverse event: those who have a realistic option
whether or not to initiate a statin. However, these results are not reflective of the entire
statin-initiating population do not justify widespread use of statins as a preventive therapy
for AKI.
These results must be interpreted in light of several important limitations. As with all
administrative claims-based studies, information on kidney function, cardiovascular risk,
and other covariates and outcomes is derived from coded reimbursement claims rather than
biomarkers and diagnostic test results. Consequently, key risk factors for AKI and CVD
such as glomerular filtration rate, blood lipids, obesity, smoking, and family history of CVD
or renal disease are either unavailable or only indirectly available through ICD-9 codes.
When present, diagnostic codes or proxies for health status (e.g. healthcare utilization,
screening, etc.) were used as potential covariates.
In particular, baseline kidney function—a strong predictor of AKI—could only be
ascertained from billing codes for CKD which are known to have low sensitivity but high
specificity.25 While we adjusted for the presence of non-ESRD CKD diagnosis codes, they
occurred infrequently (see Table 2). Yet, it is unlikely that the reliance on the codes for
CKD would have meaningfully biased the results; only information available to the
prescriber at the time of medication prescription can confound the drug-outcome
relationship. While baseline renal function is an important AKI risk factor, such information
is likely unknown at the time of prescribing in these low-risk patients.33–35 Furthermore, it
is unlikely that statin use or agent was preferentially affected by renal status given that most
statins do not require dose modifications according to renal function.
Another limitation of the study is the low sensitivity of AKI using billing codes,36 which
may underestimate AKI incidence. Yet, previous studies of community-acquired AKI have
demonstrated a comparable, low frequency of AKI despite the use of serum creatinine
measures.37–40 Furthermore, given the high specificity of billing codes for AKI,36 measures
of relative effect, such as the reported HRs, may still be unbiased.26,27
This study contains several notable strengths. First, our analysis is based on a very large
cohort from throughout the US with carefully selected comparison groups. Secondly, we
employed propensity score methods to select cohorts with similar characteristics, control for
confounding, and describe heterogeneity in a way which standard analyses would have been
unable to do. We considered several measures of CVD severity, healthcare utilization,
concurrent medication initiation, and other relevant clinical factors as adjustment factors.
Lastly, our findings were robust over sensitivity analyses, including an expanded renal
failure definition and multiple estimation techniques.
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In conclusion, statin initiation was not associated with an increased risk of AKI among most
individuals. However, there was an increased risk of AKI associated with higher-potency
simvastatin. These finding provide new information to help weigh the risks and benefits of
statins agents as the debate about their expanded use continues.
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• Statins as a class are not associated with increased AKI
• Higher-potency simvastatin carried an increased risk of AKI
• Treatment effect heterogeneity across the propensity score distribution can
explain differences in effect estimates from different propensity score-based
methods.
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Table 1
Statin potencies by formulation and dosage
Formulation Higher-potency dosages Lower-potency dosages
Atorvastatin > 10 mg ≤ 10 mg
Fluvastatin none all
Lovastatin > 40 mg ≤ 40 mg
Pravastatin none all
Rosuvastatin > 5mg ≤ 5 mg
Simvastatin > 40 mg ≤ 40 mg
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